Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Inclusion Criteria: * Men or women age ≥18 years * Histologically confirmed metastatic (stage IV) adenocarcinoma of the pancreas * Measurable disease defined per RECIST * Karnofsky Performance Status ≥50 * Expected survival ≥12 weeks * Provide written informed consent Exclusion Criteria: * CNS metastases * Prior treatment with other chemotherapy for pancreatic cancer unless used as a radiosensitizer * Radiation therapy to \>25% of the bone marrow * Clinically significant laboratory abnormalities * Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix * The need for chronic (i.e., \>7 days) oral or intravenous corticosteroid therapy with \>10mg/day prednisone equivalents * Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol * Patients who are within 28 days of radiation therapy, biologic therapy, immunotherapy, or other investigational medication. All side effects of prior treatment must have resolved at study entry. * Pregnancy or lactation